Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Obes Rev. 2024 Nov;25(11):e13811. doi: 10.1111/obr.13811. Epub 2024 Aug 12.
Weight regain and insufficient weight loss are major challenges after metabolic bariatric surgery (MBS), affecting patients' comorbidities and quality of life. The current systematic review and meta-analysis aim to assess the efficacy and safety of GLP-1 receptor agonists (GLP-1 RA) in patients with weight regain or insufficient weight loss after MBS.
A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases to find the relevant studies.
A total of 19 articles were included. The highest doses of liraglutide and semaglutide were 3 mg per day and 1 mg once weekly, respectively, in the included studies. The mean differences in weight and body mass index after treatment were -7.02 kg or 3.07 kg/m, -8.65 or -5.22 kg/m, and -6.99 kg or -3.09 kg/m for treatment durations of ≤ 6 months, 6-12 months, and >12 months with liraglutide, respectively. Additionally, weekly semaglutide showed significantly greater weight loss compared to daily liraglutide, with a mean difference of 4.15 kg. Common complications included nausea (19.1%), constipation (8.6%), abdominal pain (3.7%), and vomiting (2.4%).
Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.
体重反弹和减重不足是代谢性减重手术（MBS）后面临的主要挑战，影响患者的合并症和生活质量。本系统评价和荟萃分析旨在评估 GLP-1 受体激动剂（GLP-1RA）在 MBS 后体重反弹或减重不足患者中的疗效和安全性。
系统检索 PubMed、Embase、Scopus 和 Web of Science 数据库，以查找相关研究。
共纳入 19 项研究。纳入研究中，利拉鲁肽和司美格鲁肽的最高剂量分别为每日 3mg 和每周 1mg。治疗后体重和体质量指数的平均差异分别为：利拉鲁肽治疗持续时间≤6 个月、6-12 个月和>12 个月时，分别为-7.02kg 或 3.07kg/m、-8.65kg 或-5.22kg/m 和-6.99kg 或-3.09kg/m；每周司美格鲁肽与每日利拉鲁肽相比，体重减轻更为显著，平均差异为 4.15kg。常见并发症包括恶心（19.1%）、便秘（8.6%）、腹痛（3.7%）和呕吐（2.4%）。
使用 GLP-1RA 是治疗 MBS 后体重反弹和减重不足的一种安全有效的方法。
